David A. Siegel Praxis Precision Medicines, Inc. Transaction History

Two Sigma Advisers, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.87 - $1.71 $7,917 - $15,561	-9,100 Reduced 36.69%	15,700 $26,000
Q2 2023 Aug 14, 2023	SELL	$0.83 - $1.18 $122,093 - $173,578	-147,100 Reduced 85.57%	24,800 $28,000
Q1 2023 May 15, 2023	SELL	$0.8 - $4.98 $220,640 - $1.37 Million	-275,800 Reduced 61.6%	171,900 $139,000
Q4 2022 Feb 14, 2023	SELL	$1.88 - $36.45 $105,468 - $2.04 Million	-56,100 Reduced 11.14%	447,700 $1.07 Million
Q3 2022 Nov 14, 2022	BUY	$2.5 - $37.95 $707,000 - $10.7 Million	282,800 Added 127.96%	503,800 $1.14 Million
Q2 2022 Aug 15, 2022	BUY	$1.75 - $11.34 $286,475 - $1.86 Million	163,700 Added 285.69%	221,000 $541,000
Q1 2022 May 16, 2022	SELL	$10.21 - $20.29 $54,113 - $107,537	-5,300 Reduced 8.47%	57,300 $585,000
Q4 2021 Feb 14, 2022	BUY	$16.76 - $22.99 $546,376 - $749,474	32,600 Added 108.67%	62,600 $1.23 Million
Q3 2021 Nov 15, 2021	BUY	$13.15 - $22.56 $77,585 - $133,104	5,900 Added 24.48%	30,000 $555,000
Q2 2021 Aug 16, 2021	BUY	$18.28 - $33.05 $440,548 - $796,504	24,100 New	24,100 $441,000

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $3.54B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.